Table II.

Association between NLRX1, TRAF6 and NF-κB expression levels and the clinicopathologic features of patients with gastric cancer.

A, NLRX1 expression levels
Clinicopathological variables	Number of patients	Positive expression	Negative expression	P-value
Age, years				0.955
≤65	27	8	19
>65	33	10	23
Sex				0.431
Male	51	14	37
Female	9	4	5
Tumor size, cm				0.012
<5	28	13	15
≥5	32	5	27
Vascular invasion				0.010
Yes	35	6	29
No	25	12	13
Neural invasion				<0.001
Yes	26	1	25
No	34	17	17
Lymph node metastasis				0.011
Yes	29	4	25
No	31	14	17
Differentiation				0.001
Poorly	27	2	25
Moderately-to-well	33	16	17
Gross stage				0.005
Early	8	6	2
Advanced	52	11	41
Clinical stage				<0.001
I/II	34	17	17
III/IV	26	1	25
B, TRAF6 expression levels
Clinicopathological variables	Number of patients	Positive expression	Negative expression	P-value
Age, years				0.180
≤65	27	17	10
>65	33	20	13
Sex				0.284
Male	51	33	18
Female	9	4	5
Tumor size, cm				<0.001
<5	28	10	18
≥5	32	27	5
Vascular invasion				<0.001
Yes	35	29	6
No	25	8	17
Neural invasion				0.002
Yes	26	22	4
No	34	15	19
Lymph node metastasis				<0.001
Yes	29	25	4
No	31	12	19
Differentiation				0.001
Poorly	27	23	4
Moderately-to-well	33	14	19
Gross stage				<0.001
Early	8	0	8
Advanced	52	37	15
Clinical stage				0.002
I/II	34	15	19
III/IV	26	22	4
C, NF-κB expression levels
Clinicopathological variables	Number of patients	Positive expression	Negative expression	P-value
Age, years				0.957
≤65	27	17	10
>65	33	21	12
Sex				0.111
Male	51	38	13
Female	9	4	5
Tumor size, cm				0.020
<5	28	12	16
≥5	32	26	6
Vascular invasion				0.002
Yes	35	28	7
No	25	10	15
Neural invasion				0.017
Yes	26	21	5
No	34	17	17
Lymph node metastasis				0.007
Yes	29	24	5
No	31	15	16
Differentiation				0.015
Poorly	27	22	5
Moderately-to-well	33	16	17
Gross stage				<0.001
Early	8	0	8
Advanced	52	39	13
Clinical stage				0.017
I/II	34	17	17
III/IV	26	21	5

NLRX1, NOD-like receptor X1; TRAF6, tumor necrosis factor receptor-associated factor 6.